TAK Quote, Financials, Valuation and Earnings

Daiichi Sankyo has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of 12.77%. Takeda Pharmaceutical's return on equity of 1.49% beat Daiichi Sankyo's return on equity of 18.11%.

Takeda Pharmaceutical has a consensus price target of $17.00, signalling upside risk potential of 15.46%. On the other hand Daiichi Sankyo has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Daiichi Sankyo, analysts believe Takeda Pharmaceutical is more attractive than Daiichi Sankyo.

Takeda Pharmaceutical has a beta of 0.223, which suggesting that the stock is 77.69% less volatile than S&P 500. In comparison Daiichi Sankyo has a beta of 0.367, suggesting its less volatile than the S&P 500 by 63.316%.

Takeda Pharmaceutical has a quarterly dividend of $0.34 per share corresponding to a yield of 4.52%. Daiichi Sankyo offers a yield of 1.73% to investors and pays a quarterly dividend of $0.21 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Daiichi Sankyo pays out 38.65% of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Daiichi Sankyo quarterly revenues of $3.2B. Takeda Pharmaceutical's net income of -$676.5M is lower than Daiichi Sankyo's net income of $406M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.46x while Daiichi Sankyo's PE ratio is 22.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.57x versus 3.53x for Daiichi Sankyo. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of 21.63%. Takeda Pharmaceutical's return on equity of 1.49% beat Pfizer's return on equity of 8.72%.

Takeda Pharmaceutical has a consensus price target of $17.00, signalling upside risk potential of 15.46%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Pfizer has higher upside potential than Takeda Pharmaceutical, analysts believe Pfizer is more attractive than Takeda Pharmaceutical.

Takeda Pharmaceutical has a beta of 0.223, which suggesting that the stock is 77.69% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Takeda Pharmaceutical has a quarterly dividend of $0.34 per share corresponding to a yield of 4.52%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Takeda Pharmaceutical quarterly revenues are $6.9B, which are smaller than Pfizer quarterly revenues of $13.7B. Takeda Pharmaceutical's net income of -$676.5M is lower than Pfizer's net income of $3B. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.46x while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.57x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -24.41%. Takeda Pharmaceutical's return on equity of 1.49% beat PeptiDream's return on equity of 34.1%.

Takeda Pharmaceutical has a consensus price target of $17.00, signalling upside risk potential of 15.46%. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.

Takeda Pharmaceutical has a beta of 0.223, which suggesting that the stock is 77.69% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.523, suggesting its less volatile than the S&P 500 by 47.679%.

Takeda Pharmaceutical has a quarterly dividend of $0.34 per share corresponding to a yield of 4.52%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than PeptiDream quarterly revenues of $27.8M. Takeda Pharmaceutical's net income of -$676.5M is lower than PeptiDream's net income of -$6.8M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.46x while PeptiDream's PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.57x versus 4.93x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -11.44%. Takeda Pharmaceutical's return on equity of 1.49% beat Nxera Pharma's return on equity of -8.65%.

Takeda Pharmaceutical has a consensus price target of $17.00, signalling upside risk potential of 15.46%. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.

Takeda Pharmaceutical has a beta of 0.223, which suggesting that the stock is 77.69% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.646%.

Takeda Pharmaceutical has a quarterly dividend of $0.34 per share corresponding to a yield of 4.52%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Takeda Pharmaceutical's net income of -$676.5M is lower than Nxera Pharma's net income of -$5M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 67.46x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.57x versus 2.85x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.